{"id":462,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-synchronisierung-der-phase-3-daten-fur-1-2026","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/survodutide-synchronize-1-2026-phase-3-data\/","title":{"rendered":"Survodutide in SYNCHRONIZE-1: Die 2026-Phase 3 Zahlen im Kontext"},"content":{"rendered":"
SYNCHRONIZE-1 ist die bisher gr\u00f6\u00dfte ver\u00f6ffentlichte Survodutid-Fettleibigkeitsstudie. Der n\u00fctzliche Beweis liegt im vollst\u00e4ndigen Nenner, Sch\u00e4tzwert, der Placebo-Reaktion und dem Muster unerw\u00fcnschter Ereignisse \u2013 und nicht in einem einzigen Schlagzeilenprozentsatz.<\/p>
Was die Aufzeichnung zeigt<\/h2>
Die Studie umfasste randomisiert 725 Erwachsene mit Adipositas ohne Diabetes.<\/li>
In der Woche 76 betrug die mittlere Gewichtsver\u00e4nderung \u221212.2% und \u221213.0% in den beiden Survodutid-Gruppen im Vergleich zu \u22125.4% unter Placebo.<\/li>
Gastrointestinale Nebenwirkungen traten bei 80.9% und 89.7% der Survodutid-Teilnehmer im Vergleich zu 47.9% mit Placebo auf.<\/li><\/ul><\/div><\/div>Originale redaktionelle Darstellung des Forschungskontexts. Es handelt sich nicht um eine Studienfigur, ein Patientenbild, ein Produktfoto oder eine Darstellung von Versuchsmaterial.<\/figcaption><\/figure>
Studienprotokoll<\/h2>
Der Behandlungsschema-Sch\u00e4tzwert berichtete \u00fcber mittlere \u00c4nderungen von \u221212.2% (95% CI, \u221213.6 zu \u221210.8) und \u221213.0% (95% CI, \u221214.4 zu \u221211.6) im Vergleich zu \u22125.4% (95%). CI, \u22126.9 bis \u22124.0) f\u00fcr Placebo. Beide aktiven Vergleiche waren statistisch signifikant.<\/p>
Wochen-76-Ergebnis<\/strong>\u221212.2%, \u221213.0% und \u22125.4% mittlere Gewichts\u00e4nderung<\/span><\/div>
Zumindest 5% Reduzierung<\/strong>72.6%, 71.9% und 46.3%<\/span><\/div>
Todesf\u00e4lle<\/strong>In der ver\u00f6ffentlichten Studie wurde davon nichts berichtet<\/span><\/div><\/div><\/div>
Ergebnisse im Kontext<\/h2>
Der Responder-Endpunkt \u22655% weist in die gleiche Richtung, aber auch die Placebogruppe zeigte eine deutliche Reaktion. Das ist wichtig, weil alle Gruppen an einer kontrollierten Studie teilnahmen und nicht an einem Vergleich ohne Intervention.<\/p>
Das Papier nennt Survodutide ein Ermittlungsverfahren. Es stellt keine Austauschbarkeit zwischen der Versuchsformulierung und einem unabh\u00e4ngig beschafften Katalogmaterial her.<\/p>
Was diese Studie nicht beantworten kann<\/h2>
Die Teilnehmer hatten keinen Diabetes, daher sollte das Ergebnis nicht auf jede Stoffwechselpopulation \u00fcbertragen werden.<\/p>
Ein einphasiges 3-Papier kann keine Fragen zur langfristigen Verwendung nach der Zulassung, zu seltenen Ereignissen oder zu einem unabh\u00e4ngigen Forschungslos beantworten.<\/p>","protected":false},"excerpt":{"rendered":"
SYNCHRONIZE-1 ist die bisher gr\u00f6\u00dfte ver\u00f6ffentlichte Survodutid-Fettleibigkeitsstudie. Der n\u00fctzliche Beweis liegt im vollst\u00e4ndigen Nenner, Sch\u00e4tzwert, der Placebo-Reaktion und dem Muster unerw\u00fcnschter Ereignisse \u2013 und nicht in einem einzigen Schlagzeilenprozentsatz.<\/p>","protected":false},"author":1,"featured_media":627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Published study case","pim_evidence_level":"Randomized phase 3 human trial; investigational intervention","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\n
Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD<\/title>\n<meta name=\"description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/survodutide-synchronisierung-der-phase-3-daten-fur-1-2026\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\" \/>\n<meta property=\"og:description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/survodutide-synchronisierung-der-phase-3-daten-fur-1-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Survodutide in SYNCHRONIZE-1: Die 2026-Phase 3 Zahlen im Kontext - NHD","description":"SYNCHRONIZE-1 ist die bisher gr\u00f6\u00dfte ver\u00f6ffentlichte Survodutid-Fettleibigkeitsstudie. Der n\u00fctzliche Beweis liegt im vollst\u00e4ndigen Nenner, Sch\u00e4tzwert, Placebo-Reaktion und \u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/survodutide-synchronisierung-der-phase-3-daten-fur-1-2026\/","og_locale":"de_DE","og_type":"article","og_title":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","og_description":"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026","og_url":"https:\/\/nhdbio.com\/de\/survodutide-synchronisierung-der-phase-3-daten-fur-1-2026\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","url":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","name":"Survodutide in SYNCHRONIZE-1: Die 2026-Phase 3 Zahlen im Kontext - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SYNCHRONIZE-1 ist die bisher gr\u00f6\u00dfte ver\u00f6ffentlichte Survodutid-Fettleibigkeitsstudie. Der n\u00fctzliche Beweis liegt im vollst\u00e4ndigen Nenner, Sch\u00e4tzwert, Placebo-Reaktion und \u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=462"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/462\/revisions"}],"predecessor-version":[{"id":514,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/462\/revisions\/514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/627"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Wissenschaftler](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\")